175 related articles for article (PubMed ID: 30108156)
21. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
22. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
24. Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma.
Li L; Rao X; Wen Z; Ding X; Wang X; Xu W; Meng C; Yi Y; Guan Y; Chen Y; Wang J; Jun L
Oncol Lett; 2020 Apr; 19(4):2739-2748. PubMed ID: 32218826
[TBL] [Abstract][Full Text] [Related]
25. Targeted 595-gene genomic profiling demonstrates low tumor mutational burden in olfactory neuroblastoma.
Friedman J; Schumacher JK; Papagiannopoulos P; Al-Khudari S; Tajudeen BA; Batra PS
Int Forum Allergy Rhinol; 2021 Jan; 11(1):58-64. PubMed ID: 32558242
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.
Ali SM; Yao M; Yao J; Wang J; Cheng Y; Schrock AB; Chirn GW; Chen H; Mu S; Gay L; Elvin JA; Suh J; Miller VA; Stephens PJ; Ross JS; Wang K
Cancer; 2017 Sep; 123(18):3628-3637. PubMed ID: 28581676
[TBL] [Abstract][Full Text] [Related]
27. Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines.
Fadlelmola FM; Zhou M; de Leeuw RJ; Dosanjh NS; Harmer K; Huntsman D; Lam WL; Banerjee D
Mol Cancer; 2008 Jan; 7():2. PubMed ID: 18179710
[TBL] [Abstract][Full Text] [Related]
28. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
29. Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas.
Singh K; Lezama LS; Kurzer J; Oak J; Schultz LM; Walkush A; Cheng TC; Chen EH; May WA; Chang C; Link MP; Advani RH; Suarez CJ; Natkunam Y
Am J Surg Pathol; 2023 Jan; 47(1):81-90. PubMed ID: 36001451
[TBL] [Abstract][Full Text] [Related]
30. Exportin 1-mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma.
Caillot M; Miloudi H; Taly A; Profitós-Pelejà N; Santos JC; Ribeiro ML; Maitre E; Saule S; Roué G; Jardin F; Sola B
Mol Oncol; 2023 Dec; 17(12):2546-2564. PubMed ID: 36727672
[TBL] [Abstract][Full Text] [Related]
31.
Miloudi H; Bohers É; Guillonneau F; Taly A; Gibouin VC; Viailly PJ; Jego G; Grumolato L; Jardin F; Sola B
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33007990
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations.
Wang K; McDermott JD; Schrock AB; Elvin JA; Gay L; Karam SD; Raben D; Somerset H; Ali SM; Ross JS; Bowles DW
Ann Oncol; 2017 Apr; 28(4):748-753. PubMed ID: 28327999
[TBL] [Abstract][Full Text] [Related]
33. Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.
Juskevicius D; Jucker D; Dietsche T; Perrina V; Rufle A; Ruiz C; Dirnhofer S; Tzankov A
Lab Invest; 2018 Nov; 98(11):1487-1499. PubMed ID: 30087457
[TBL] [Abstract][Full Text] [Related]
34. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
35. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
[TBL] [Abstract][Full Text] [Related]
37. Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.
Alcoceba M; García-Álvarez M; Chillón MC; Jiménez C; Medina A; Antón A; Blanco O; Díaz LG; Tamayo P; González-Calle V; Vidal MJ; Cuello R; Díaz Gálvez FJ; Queizán JA; Martín A; González M; García-Sanz R; Sarasquete ME
Br J Haematol; 2021 Nov; 195(4):542-551. PubMed ID: 34312841
[TBL] [Abstract][Full Text] [Related]
38. Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Hav M; Colombo A; Chavez EA; Nissen M; Wang X; Miyata-Takata T; Lam V; Viganò E; Woolcock BW; Telenius A; Li MY; Healy S; Ghesquiere C; Kos D; Goodyear T; Veldman J; Zhang AW; Kim J; Saberi S; Ding J; Farinha P; Weng AP; Savage KJ; Scott DW; Krystal G; Nelson BH; Mottok A; Merchant A; Shah SP; Steidl C
Cancer Discov; 2020 Mar; 10(3):406-421. PubMed ID: 31857391
[TBL] [Abstract][Full Text] [Related]
39. The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy.
Xu LB; Zhao ZG; Xu SF; Zhang XX; Liu T; Jing CY; Zhang SG; Yu SJ
Int J Biol Markers; 2020 Sep; 35(3):14-22. PubMed ID: 32520634
[TBL] [Abstract][Full Text] [Related]
40. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
